English Deutsch 中文
  • Innovative Solutions
  • Expert Support and Knowledge
  • Reliable Cooperation
Menu Deutsch 中文

Eddingpharm Gains China Rights for Cancer Drug from Syndax

Sep. 4, 2013

Syndax Pharmaceuticals, which is developing epigenetic therapies for treatment-resistant cancers, and Eddingpharm, a leading specialty pharmaceutical company in China, entered into a licensing, development and commercialization agreement on Sept. 4, 2013, that gives Eddingpharm exclusive rights to develop, market and sell entinostat in China and certain other Asian countries/regions. Financial details were not disclosed but include milestone payments and royalties on future entinostat sales. As part of the agreement, Eddingpharm may participate in entinostat’s first three global Phase 3 registration trials, while Eddingpharm will have the right to explore further indications for entinostat in China.